In the above article [Xiang H, Nguyen CB, Kelley SK, Dybdal N, and Escandón E (2004) Drug Metab Dispos 32:1230-1238], the wrong Figs. 2, 3, 5, 6, 7, and 10 appeared. The correct figures follow. The online version has been corrected in departure from the print version.
Fig. 2.
Recovery of Apo2L/TRAIL in human serum determined by ELISA and an alamarBlue bioassay. Apo2L/TRAIL at 1 μg/ml, 10 μg/ml, and 25 μg/ml was incubated for 0, 1, 2, 4, 8, 24, and 48 h at 37°C with pooled human serum. A, the percentage of Apo2L/TRAIL recovered from human serum by ELISA was normalized to the control group. B, Apo2L/TRAIL bioactivity at different concentrations and time points was compared with the control group.
Fig. 3.
Concentration versus time profiles for Apo2L/TRAIL. 125I-Apo2L/TRAIL serum concentrations were determined by analysis of TCA-precipitable radioactivity at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after administration. Nanogram-equivalents of precipitable 125I-Apo2L/TRAIL were calculated and are shown on the y-axis. Apo2L/TRAIL serum concentrations were analyzed by ELISA. Data are from three mice per time point.
We regret any confusion or inconvenience caused by this printing error.
Fig. 5.
Nanogram-equivalents of total 125I-Apo2L/TRAIL measured in tissues and tumor. Total radioactivity of 125I-Apo2L/TRAIL in kidney, liver, lung, spleen, tumor, and plasma was measured at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after dosing with 125I-Apo2L/TRAIL (A) or 125I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL (B). Nanogram-equivalents of 125I-Apo2L/TRAIL were calculated as described under Materials and Methods and are shown on the y-axis.
Fig. 6.
Total 125I-Apo2L/TRAIL in kidney and tumor. Figures represent 125IApo2L/TRAIL radioactivity (cpm/g) in kidney (A) and tumor (B) at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after dosing 125I-Apo2L/TRAIL or 125I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL.
Fig. 7.
Nanogram-equivalents of TCA-precipitable 125I-Apo2L/TRAIL in tissues and tumor. TCA-precipitable 125I-Apo2L/TRAIL in kidney, liver, lung, spleen, tumor, and plasma were measured at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after dosing 125I-Apo2L/TRAIL (A) or 125I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL (B). Nanogram-equivalents of 125I-Apo2L/TRAIL were calculated and are shown on the y-axis.
Fig. 10.
Tissue-to-blood ratios of 125I-Apo2L/TRAIL in tissue. Tissue-to-blood ratios of 125I-Apo2L/TRAIL in kidney, liver, blood pool, brain, lung, stomach, and intestine at 15 min and 1 h after dosing with 125I-Apo2L/TRAIL (A) or 125I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL (B).
- The American Society for Pharmacology and Experimental Therapeutics